| Oncogenic function of p34SEI-1 via NEDD41mediated PTEN ubiquitination/degradation and activation of the PI3K/AKT pathway. | None |
| PLC-gamma and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. | None |
| DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110alpha (H1047R). | None |
| Te structure and function of the p110alpha enzyme and two of its most common oncogenic mutations. [Review] | None |
| Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells. | None |
| Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. | None |
| Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. | None |
| HIV-1 Nef and KSHV oncogene K1 synergistically promote angiogenesis by inducing cellular miR-718 to regulate the PTEN/AKT/mTOR signaling pathway. | None |
| Activation of diverse signalling pathways by oncogenic PIK3CA mutations. | None |
| Hijacking Dlg1 for oncogenic phosphatidylinositol 3-kinase activation in human epithelial cells is a conserved mechanism of human adenovirus E4-ORF1 proteins. | None |
| Activation of PI3Kalpha by physiological effectors and by oncogenic mutations: structural and dynamic effects. | None |
| Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant. | None |
| Studied the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant. | None |
| Oncogenic activity of the regulatory subunit p85beta of phosphatidylinositol 3-kinase (PI3K). | None |
| Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. | None |
| Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects. | None |
| Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. | None |
| oncogenic Pik3ca(H1047R) activates a multipotent genetic program in normally lineage-restricted populations at the early stage of tumour initiation, setting the stage for future intratumoural heterogeneity | None |
| Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K. | None |
| We have observed a 4% oncogenic mutation frequency of the PIK3CA gene, which plays a minor role in the development of OSCC in an Indian population. | None |